Transaction · 0001620548-26-000009

Pena Luis C.

Pena Luis C., PRES, CEO, reported a transaction classified as grant at Evommune, Inc. involving 1115.000000 shares for an estimated $7827.30. Reported holdings after the transaction were 631573.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code APRES, CEO
EVMNEvommune, Inc.
Trade date
Sep 30, 2026
Filing date
Oct 15, 2026
View on SEC Insider profile
Estimated value$7.82kShares × reported price
Shares traded1.11k$7.02 per share
Holdings after631kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 15 calendar days after the transaction date.

EVMN price since this filing

Daily closing prices, with the filing date and available return windows
EVMN · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001620548-26-000009
Common Stock
Transaction date
Sep 30, 2026
Filed Oct 15, 2026, 08:28 PM · 15d delay
Shares
1,115 sh
$7.02 per share
Estimated value
$7.82k
Computed from shares × price
Holdings after
631,573 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Delayed Filing Direct Ownership
Filing-only score

-22 points

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • grant_or_award-22 points

    transaction_code = A

    Grant or award transactions are scheduled compensation, not discretionary.
  • delayed_filing-6 points

    reporting_delay_days = 15

    Filing delay exceeds the configured threshold.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Represents shares acquired under the non-qualified component of the Evommune, Inc. 2025 Employee Stock Purchase Plan ("ESPP").

  2. F2

    In accordance with current ESPP offering standards, these shares were purchased at 85% of the closing price of the Issuer's common stock on September 30, 2026.

Original filing · 0001620548-26-000009
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

EVMN